Table 2.
Patient characteristics by presence of ICD after propensity match
| Factor | Non-ICD Group (n=631) | ICD Group (n=631) | P Value |
|---|---|---|---|
| Age | 72.0±10.8 | 70.5±11.6 | 0.02 |
| Men | 439 (69.6) | 428 (67.8) | 0.50 |
| Black race | 128 (20.3) | 111 (17.6) | 0.22 |
| BMI (kg/m2) | 28.4±6.1 | 28.9±6.0 | 0.19 |
| BMI group (kg/m2) | 0.65 | ||
| <18.5 | 6 (0.95) | 4 (0.63) | |
| 18.5–24.9 | 182 (28.8) | 173 (27.4) | |
| 25–29.9 | 233 (36.9) | 219 (34.7) | |
| ≥30 | 206 (32.6) | 231 (36.6) | |
| Missing | 4 (0.63) | 4 (0.63) | |
| eGFR (ml/min per 1.73 m2) | 42.2±11.8 | 42.8±11.6 | 0.33 |
| CKD stage, by eGFR (ml/min per 1.73 m2) | 0.11 | ||
| 45–59 | 305 (48.3) | 303 (48.0) | |
| 30–44 | 219 (34.7) | 227 (36.0) | |
| 15–29 | 91 (14.4) | 96 (15.2) | |
| <15 | 16 (2.5) | 5 (0.79) | |
| Diabetes | 186 (29.5) | 192 (30.4) | 0.71 |
| Hypertension | 486 (77.0) | 488 (77.3) | 0.89 |
| Congestive heart failure | 338 (53.6) | 347 (55.0) | 0.61 |
| Coronary artery disease | 338 (53.6) | 333 (52.8) | 0.78 |
| Cerebrovascular disease | 82 (13.0) | 90 (14.3) | 0.51 |
| Peripheral vascular disease | 33 (5.2) | 31 (4.9) | 0.80 |
| Coronary revascularization | 88 (13.9) | 91 (14.4) | 0.81 |
| Ventricular arrhythmia | 18 (2.9) | 31 (4.9) | 0.06 |
| Albumin (g/dl) | 4.0±0.50 | 4.0±0.50 | 0.04 |
| Hemoglobin (g/dl) | 12.3±1.9 | 12.5±1.9 | 0.02 |
| LVEF (%) | 26.7±9.2 | 27.2±8.2 | 0.28 |
| Malignancy | 115 (18.2) | 99 (15.7) | 0.23 |
| Use of ACEIs/ARBs | 573 (90.8) | 576 (91.3) | 0.77 |
| Use of statins | 480 (76.1) | 490 (77.7) | 0.50 |
| Use of β-blockers | 577 (91.4) | 581 (92.1) | 0.68 |
| Smoking | 0.42 | ||
| No | 488 (77.3) | 506 (80.2) | |
| Yes | 51 (8.1) | 48 (7.6) | |
| Missing | 92 (14.6) | 77 (12.2) | |
| Insurance | 0.15 | ||
| Private | 129 (20.4) | 107 (17.0) | |
| Medicare/Medicaid | 481 (76.2) | 509 (80.7) | |
| Missing | 21 (3.3) | 15 (2.4) |
Data are given as n (%) or means±SD unless otherwise indicated. ICD, implantable cardioverter-defibrillator; BMI: body mass index; LVEF, left ventricular ejection fraction; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.